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W J  H M VAN DEN BOSCH Introduction
C P VAN SCHAYCK A
J MOLEMA
STHMA is a common disease in general practice, for which 
a pathognomonic test is lacking. At this moment, diagnosis 
of asthma by a general practitioner (GP) is based on a positive 
history of bronchial symptoms, atopic disease(s), occupational
C VANWEEL
exposure to known sensitizing agents, and the findings at a phys­
ical examination.1'3 GPs usually diagnose asthma on the basis of 
symptoms only, without the use of additional testing, such as 
spirometry or al lergy testing. This may be one of the reasons thatSUMMARY
Background. Assessing bronchial hyper-responsiveness 
(BHR) is a main diagnostic criterion o f asthma. Provocation 
testing is not readily available in general practice, but peak explanation for the increase in asthma morbidity.4,5 As asthma is
patients remain unrecognized —  ‘underdiagnosis ’ that leads to 
‘undertreatment’ or a delay in treatment1,3 —  and might be an
expiratory flow (PEF) is. Several guidelines promote the 
use o f PEF variability as a diagnostic too l for BHR. This 
study tested the agreement between histamine challenge 
testing and PEF variability, and the consequences for diag­
nosing asthma
Aim. To investigate the possibility o f assessing BHR by PEF 
variability, using a histamine provocation test as a refer­
ence.
characterized by reversible airflow obstruction, BHR, and 
inflammation of the bronchial tubes, spirometry can confirm 
both the reversible airflow obstruction and the hyper-responsi ve- 
ness.6 Additional use of spirometry can facilitate the interpreta­
tion of symptoms and the identification of asthma from the com­
monly presented respiratory symptoms in general practice. 
Bronchial obstruction, one of the cornerstones of asthma diagno­
sis, is easy to assess. However, it might be absent at the time of
Method. Subjects with signs or symptoms indicating asthma testing.7 Therefore, assessment of BHR is also proposed in the
(persistent or recurrent respiratory symptoms or signs o f diagnosis of asthma.6-8 Its assessment is considered to be a main 
reversible bronchial obstruction) fn = 323) were studied.
They had been identified in a population screening for asth­
ma. A histamine provocation test and PEF variability were 
assessed over a three-week period. Asthma was defined as
signs or symptoms together with a reversib le  a ir f lo w
diagnostic criterion2'9 to distinguish between healthy subjects and 
subjects with respiratory diseases,11 although there is conflicting 
evidence in this respect," probably arising from variation in the 
population studied.10 
BHR can be assessed by bronchial provocation testing or by
obstruction or BHR to the histamine challenge test. BHR measuring PEF variability.1214 This paper will focus on the value
was defined as a PC20 histamine of ^ 8  mg/ml or a PEF vari­
ability of > 15%. Overall correlation between PC20 and PEF 
va r ia b il i ty  was ca lcu la ted using S pea rm an 's  rho. 
Furthermore, a decision tree was constructed to clarify the 
role of BHR in diagnosing asthma.
Results. Thirty-two patients had a reversib ility in forced 
expiratory volume in 1 second (FEV-j) o f >9% predicted, 131 
patients showed a PC20 o f < 8  and 11 patients had a PEF 
variability of >15%. Overall correlation was poor at only  
-0.27 (? <0.0001). One hundred and fourteen o f the 131 
patients diagnosed as having asthma when the histamine 
challenge test was used were not diagnosed by PEF vari­
ability.
Conclusion. PEF variability cannot replace bronchial provo­
cation testing in assessing BHR. This indicates that PEF 
variability and bronchial provocation do not measure the 
same aspects of BHR. If BHR testing is required in diagnos­
ing asthma, a bronchial provocation test has to be used in 
general practice as well.
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of PEF variability in assessing BHR. Chest physicians usually 
test BHR by a provocation test, not only as a diagnostic routine, 
but also as an indicator for adjusting or readjusting medication.'9 
For the majority of asthma patients treated by GPs, BHR testing 
is quite an exception, as bronchial provocation would require 
easy access to a lung function laboratory. However, in general 
practice, PEF measurement has already established its place for 
measuring bronchial obstruction.7 When the PEF is measured at 
least twice daily, the PEF variability, which reflects the degree of 
bronchial responsiveness, can be calculated as well.15
assessment requires only low technology: the five ‘Ps’ of patient, 
PEF meter, pocket calculator, pencil, and paper. In this way, ade­
quate diagnosis of asthma might be within reach of general prac­
tice (Figure 1).
PEF variability measures the variation in airway calibre under 
everyday life or work conditions, and PC20 measures changes in 
bronchial calibre under standardized challenge. Several studies 
have been performed on the correlation between PC20 and PEF 
variability,12,1(1,17 but there remains controversy over their find­
ings. Asthma medication might interfere with both PEF and PC20 
measurements,17 and the use of medication might have been a 
factor interfering with the results of these studies. It was for this 
reason that we carried out a study on patients without a previous 
asthma diagnosis,18 which has been described only once before 
in a random sample from a general practice population.19 This 
study was carried out to determine if PC20 histamine can be 
replaced by PEF variability. It assessed histamine bronchial
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provocation testing and the PEF variability of subjects with signs Spirometry 
or symptoms indicating asthma. Our hypothesis was that a peak 
flow variability of >15% is as successful in assessing BHR as 
PC20 histamine. If true, mapping BHR in general practice would 
be possible this way.
Method
Design
In this explanatory study, PEF variability and PC20 histamine 
were compared in 323 subjects reporting signs or symptoms of 
asthma in a population screening for asthma.18
Subjects
Patients were recruited from a screening for asthma in an open 
population. A total of 1155 randomly selected subjects were 
screened. The selection procedure has been described extensively 
elsewhere.18 In summary, all subjects were adults between 25 
and 70 years old, recruited from the patients of 10 general prac­
tices. Included in this study were subjects with one or more of 
the signs or symptoms indicating asthma (Table I).20 Excluded 
were those who were unable to use a PEF device or to complete 
a diary.
Asthma definition
To diagnose asthma, we used an adapted version of the algorithm 
of Sheffer et al (Figure l ).6 All our subjects had a bronchoprovo- 
cation test and a three-week monitoring of their PEF. Asthma 
was defined as symptoms and a reversibility after bronchodila- 
tion with 800 mg of salbutamol of at least 9% predicted7 or 
BHR, i.e. a PC20 of ^  8 mg/ml.9
Measurement scheme
All subjects eligible for study were visited and instructed at 
home by five trained investigators. After three weeks of measur­
ing PEF twice a day, they were invited to a lung function labora­
tory.
Questionnaire
Subjects were screened using an asthma questionnaire extended 
with questions of specific and non-specific BHR and smoking 
history.20 Data were collected by five trained investigators.
Diary and PEF measurement
All patients were visited at home and trained in how to perform 
and to use a mini-Wright peak flow meter, and how to register 
PEF in a diary. They recorded their PEF for three weeks, twice a 
day at the same time in the morning and in the evening. For
analysis, the highest value of three measurements was taken. The 
diurnal PEF index was calculated as:21
DCC . .. _  PEFhjghest -  PEF  lowest ^  1 nno/ 
r tz rv a r ia b i l i ty  “  '---------------- — X lO O /b
PEEmean
In order to test for learning effects, the mean morning PEF val­
ues on days l-7 were first compared with the mean morning val­
ues on days 8-21. Since this showed no significant difference 
(P>0.2, paired /-test), measurements for the total period of 21 
days were used for analysis. For analysis, the mean diurnal PEF 
index was calculated by taking the arithmetic mean of 21 daily 
PEF variabilities.
FVC and FEVi were assessed by means of an integrating 
flowmeter (Microspiro HI-298, Chest Corporation, Japan), 
according to the standards of the European Respiratory Society 
(ERS).9,22 Reversibility was assessed 15 min after administration 
of 800 mg of salbutamol inhaled by means of a spacer, and 
expressed as percentage predicted.7,23,24
Bronchial provocation testing
At the University Lung Center, Dekkerswald, lung function mea­
surement was carried out during an exacerbation-free period. 
Twelve hours before lung function testing, no bronchodilator 
was used. Trained lung function technicians measured FVC, 
FEVi, and bronchial responsiveness to histamine (PC20 histamine 
values) by means of the Microspiro HI-298 according to ERS 
standards.9 Bronchial provocation with histamine (PC20) was 
assessed according to Cockcroft and Hargreave.10 The provoca- 
tional concentration of histamine causing a 20% fall in FEVi 
from the baseline value (PC20) was calculated by linear interpola­
tion of the difference in FEVi versus 2log PC20. Challenging 
started with saline and subsequent increases in histamine from a 
dose of 0.030 up to a concentration of 32 mg/ml.25
Analysis
Overall correlation between PC20 and PEF variability was calcu­
lated with Spearman’s rho. Differences between groups were 
tested using Student’s i-test or chi-square statistics as appropri­
ate. As significance level, P < 0.05 (two-tailed) was used.
In a second analysis, the diagnostic properties of PEF variabi­
lity were compared with PC20- For this analysis, a decision tree 
was used. In the first step, all subjects were included with signs 
or symptoms. In the second step, reversible bronchial obstruction 
on testing was included. If subjects did meet this criterion, the 
diagnosis of ‘asthma’ was established, which concluded diagnos­
tic testing. For all other subjects, BHR testing was introduced as 
the third step, and all subjects with a positive test result were 
considered asthmatic. This step was first analysed using the hist­
amine challenge test result followed by diagnostic allocation 
when PEF replaced the histamine challenge. PEF-related classifi­
cation was compared for correctness with the standard histamine 
challenge-based diagnosis.
To examine the influence of the cut-off point of PEF variabili­
ty, a series of tables was produced to show the influence of the 
cut-off point of a PEF variability on the test characteristics 
(Table 2).
This study was approved by the ethics committee o f the 
University Lung Center, Dekkerswald. All participants gave 
informed consent.
Results
On screening, 529 subjects had signs or symptoms that could 
indicate asthma. Of these, 323 met the inclusion criteria and were 
willing to participate (Table 3). Non-participants (n = 206) did 
not differ significantly in age, smoking habits or FEV1 % predict­
ed, but showed a lower reversibility of FEVi after bronchodila- 
tion (2.89% versus 4.05%, P = 0.002) compared with the partici­
pants (Table 3). All 323 subjects were able to perform PEF mea­
surement and to complete a diary. Five incomplete patient PEF 
diaries could not be evaluated and had to be excluded from the 
analysis. The overall correlation between PC20 and PEF variability 
was -0.27 (P< 0.0001).
In the second part of the analysis, the decision tree was fol­
lowed (Figure 2). In the first step, reversible bronchial obstruc-
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tion of FEVi of > 9% predicted was included, which was present 
in 32 subjects, leading to the diagnosis ‘asthma’ . Analysis of 
BHR in this part of the tree is not further discussed, as its diag­
nostic testing in this group would be spurious.
The second step showed that, of the group of 291 patients 
with respiratory symptoms but without a reversible airflow 
obstruction, 111 had a PC20 of < 8 mg/ml leading to the diagno­
sis ‘asthma’. The third step showed that, if a PEF variability of > 
15% was used for BHR instead of bronchial provocation testing, 
only nine of these 111 cases would have been diagnosed.
Inclusion of PEF would have resulted in an overall frequency of 
asthma of 0.13 (32 with a reversible airflow obstruction and 
nine with a PEF variability of >15% = 41/318) instead of 0.45 
(143/318).
As shown in Table 2, the cut-off point of PEF variability 
influenced the test characteristics: with a variability of > 4.56%, 
the discrimination between subjects diagnosed with ‘asthma’ on 
the basis of a PC20 histamine of <8 mg/ml proved to be optimal, 
but a substantial number of cases would still have been incor­
rectly classified.
Table 1. Questions used to determine subjects with a higher risk
of asthma.21
Subjects were asked if they suffered from
-  chronic cough on most days or nights in three consecutive 
months
-  chronic phlegm production on most days or nights in three 
consecutive months
-  more than one period of at least three weeks of cough or 
phlegm production in the previous three years
-  dyspnoea when going upstairs or walking fast on level ground
-  regular chest wheezing or whistling
-  attacks of dyspnoea with wheezing (asthmatic attacks)
-  'allergic dyspnoea' after contact with dust, cats, dogs, etc.
-  'non-allergic dyspnoea' after exercise or contact with cold air, 
cigarette smoke, etc.
Discussion
This study investigated the assessment of BHR in a general prac­
tice population of subjects with a risk of asthma using a hista­
mine provocation test and PEF variability. It was concluded that 
the correlation between PC20 histamine and PEF variability was 
low, and using PEF instead of PC20 histamine did lead to a sub­
stantially lower diagnostic classification. Therefore, PEF could 
not be recommended as a substitute for the PC20 histamine. So, 
our hypothesis that a PEF variability of 2:15% is as successful in 
assessing BHR as PC20 histamine does not hold, and this implies 
that PEF variability cannot replace the PC20 histamine provoca­
tion test. This requires a reconsideration of the diagnostic role of 
PEF, as advocated in various guidelines.1-9 
Other studies have reported correlations between PEF and
Table 2. Relation between PC20 and PEFR variability and test specifications using a cut off point of 5%, 10% and 15%.
PC20 S 8 mg/ml PC20 > 8 mg/ml Total
PEFR £ 5% 
PEFR < 5%
73
57
58
130
131
187
PEFR k 10% 
PEFR < 10%
18
112
8
180
26
292
PEFR £ 15% 
PEFR < 15%
6
124
4
184
10
308
Total 130 188 318
Test specifications 
PEFRS 5% 10% 15%
Sensitivity 
Specificity 
PPV" for PEF£ 
NPVb for PEF<
73/130 = 0.56 
130/188 » 0.69 
73/131 * 0.56 
130/187 - 0.66
18/130 = 0.14 
180/188 -  0.96 
18/26 «= 0.69 
180/292 - 0.62
6/130 = 0.05 
184/188 = 0.97 
6/10 - 0.60 
184/308 = 0.60
aPPV, positive predicted value. bNPV, negative predictive value.
Table 3. Clinical characteristics.
Participants 
(n » 323)
Non-participants
(n *  206)
P value
Male/female 
Age (years)
FEV1 (% predicted)
FEV1 (ml)
Reversibility (% predicted) 
PC20
135/188 
43±12 
95±16 
3154±800 
4±5 
7.3
73/133 
44±13 
93±15 
3008±857 
3±4 
Not available
NS
NS
NS
<0.05
<0.05
Smoking status 
(Ex)smokers/never smokers 
Pack-years
129/194
8±10
96/110 
10±11
0.131
0.183
Mean values ± SD except for PC20 where the geometric mean is given of participants only.
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tion of FEVi of > 9% predicted was included, which was present 
in 32 subjects, leading to the diagnosis ‘asthma’. Analysis of 
BHR in this part of the tree is not further discussed, as its diag­
nostic testing in this group would be spurious.
The second step showed that, of the group of 291 patients 
with respiratory symptoms but without a reversible airflow 
obstruction, 111 had a PC20 of <8 mg/ml leading to the diagno­
sis ‘asthma’. The third step showed that, if a PEF variability of > 
15% was used for BHR instead of bronchial provocation testing, 
only nine of these 111 cases would have been diagnosed.
Inclusion of PEF would have resulted in an overall frequency of 
asthma of 0.13 (32 with a reversible airflow obstruction and 
nine with a PEF variability of >15% = 41/318) instead of 0.45 
(143/318).
As shown in Table 2, the cut-off point of PEF variability 
influenced the test characteristics: with a variability of > 4.56%, 
the discrimination between subjects diagnosed with ‘asthma’ on 
the basis of a PC20 histamine of <8 mg/ml proved to be optimal, 
but a substantial number of cases would still have been incor­
rectly classified.
Table 1. Questions used to determine subjects with a higher risk
of asthma.21
Subjects were asked if they suffered from
-  chronic cough on most days or nights in three consecutive 
months
-  chronic phlegm production on most days or nights in three 
consecutive months
-  more than one period of at least three weeks of cough or 
phlegm production in the previous three years
-  dyspnoea when going upstairs or walking fast on level ground
-  regular chest wheezing or whistling
-  attacks of dyspnoea with wheezing (asthmatic attacks)
-  'allergic dyspnoea' after contact with dust, cats, dogs, etc.
-  'non-allergic dyspnoea' after exercise or contact with cold air, 
cigarette smoke, etc.
Discussion
This study investigated the assessment of BHR in a general prac­
tice population of subjects with a risk of asthma using a hista­
mine provocation test and PEF variability. It was concluded that 
the correlation between PCao histamine and PEF variability was 
low, and using PEF instead of PC20 histamine did lead to a sub­
stantially lower diagnostic classification. Therefore, PEF could 
not be recommended as a substitute for the PC20 histamine. So, 
our hypothesis that a PEF variability of > 15% is as successful in 
assessing BHR as PC20 histamine does not hold, and this implies 
that PEF variability cannot replace the PC20 histamine provoca­
tion test. This requires a reconsideration of the diagnostic role of 
PEF, as advocated in various guidelines.1,9
Other studies have reported correlations between PEF and
Table 2 . Relation between PC20 and PEFR variability and test specifications using a cut off point of 5%, 1 0 % and 15%.
PC20 i  8  mg/ml PC2o > 8 mg/ml Total
PEFR t 5% 73 58 131
PEFR < 5% 57 130 187
PEFR à 1 0 % 18 8 26
PEFR <10% 1 1 2 180 292
PEFR 2:15% 6 4 10
PEFR <15% 124 184 308
Total 130 188 318
Test specifications 
PEFR£ 5% 1 0 % 15%
Sensitivity 73/130 = 0.56 18/130 = 0.14 6/130 = 0.05
Specificity 130/188 -  0.69 180/188 = 0,96 184/188 = 0.97
PPVB for PEFs 73/131 -  0.56 18/26 « 0.69 6/10 = 0.60
NPVb for PEF< 130/187 •  0.66 180/292 «s 0.62 184/308 = 0.60
iiM fm m  I --- tiTTTiirm— --^Iiir-  11 h jh u j..... 1 -- Iim i~ n iir i ---n mi r .i 1 in.. t . unig. 1... ......................................... ~iii.Li.]jJHiiiiMU-ii'Ji-iunritiJni»mf'U«wi.lH-U-n™— ..... .11 n111. ..... 1111 —m_i n nn_i.. ..u r im .. .1 ifirniTliij—ni~ii.LH— i — 1 — i t — 'n i l  ---.1----- —  ■■~-f----- - -, r ) l nfnmrm j  Mm mu -niï m TiTirTT~~n.iiiTTTTTrrrinnnrii 1—mu in---n—T" ir~^~
“PPV, positive predicted value. bNPV, negative predictive value.
Table 3. Clinical characteristics.
Participants Non-participants Pvalue
( n -  323) (n ss 206)
Male/female 135/188 73/133 NS
Age (years) 43±12 44±13 NS
FEV1 (% predicted) 95±16 93±15 NS
FEVi (ml) 3154±800 3008*857 <0.05
Reversibility (% predicted) 4±5 3±4 <0.05
PC20 7.3 Not available
Smoking status
(Ex)smokers/never smokers 129/194 96/110 0.131
Pack-years 8 ± 1 0 1 0 ± 1 1 0.183
Mean values ± SD except for PC20 where the geometric mean is given of participants only.
British Journal of General Practice, August 1997 489
J J Den Otter, G M W Reijnen, et al Original papers
Do broncho­
provocation tests
Use bronchodilator
Results 
positive?
Asthma quite likely. 
Consider medical 
and family history and 
other tests. Consider 
other diseases.
No
Obstructions^®® 
reversed?
Yes Is asthma 
indicated?
Intensive treatment for 2-6 weeks 
with bronchodilators and anti­
inflammatory agents and PEFR 
monitoring
Obstruction 
reversed?
Obstruction only
partially or minimally
No reversed. Consider
other diseases
Is asthma the 
most likely 
diagnosis
Other disease
Severe, chronic, 
long-standing asthma Asthma
Figure 1. Algorithm for diagnosing asthma. Asthma is characterized by reversible airflow obstruction and can often be diagnosed with com­
plete certainty. However, when mixed signals are present clinically, one must consider other diseases that can also cause airflow obstruc­
tion. Sometimes, it may be impossible to distinguish among several possibilities or there may actually be coexisting diseases. This dis­
claimer is, in essence, true with any diagnosis. The general approach in diagnosing asthma is first to determine whether the patient has 
symptoms of cough, wheezing, shortness of breath or exercise intolerance. Do the symptoms appear to be episodic in nature? If so, a diag­
nosis of asthma should be strongly considered, and efforts should be made to demonstrate the reversibility of airflow obstruction after 
treatment using pulmonary function tests. If airflow obstruction is present but cannot be immediately reversed with an inhaled bronchodila­
tor, it may be necessary to treat the patient aggressively with bronchodilators and anti-inflammatory agents for up to six weeks before 
deciding that airflow obstruction is truly irreversible. If the symptoms present suggest asthma but there is no evidence of airflow obstruc­
tion, a bronchoprovocation test should be performed. If the bronchial challenge is positive, then once again a diagnosis of asthma should 
be strongly considered. At the point of considering asthma strongly, one should consider other causes of reversible airflow obstruction, 
such as heart disease, the presence of foreign bodies in airways, and chronic obstructive pulmonary disease with a reversible component. If 
such diseases are present, and there are many to consider, one must try to determine whether this disease is predominant or whether asth­
ma also coexists. When there is more than one disease present that can cause airflow obstruction, a conclusive diagnosis is difficult. 
Modifying factors that increase the probability of asthma include a personal or family history of asthma, hay fever or other allergies. It 
should be remembered at this point, however, that there are two ages of onset of asthma. Asthma that begins in childhood is almost always 
associated with a strong history of allergy and is likely to be atopic. One final consideration is that some patients with severe, longstanding 
and poorly treated asthma may develop irreversible airflow obstruction. These patients may still deserve a diagnosis of asthma if all other 
factors lead to that diagnosis, and if no other good cause for the airflow obstruction is found.
490 British Journal of General Practice, August 1997
J J Den Otter, G M W Reijnen, et al Original papers
n
Step 1: 
reversibility n
Step 2: 
histamine 
challenge
n
Symptoms 
present 
at the start
Reversibility 2: 9%
12
Step 3: 
PEF 
variability
& 15%
< 15%
n
1
19
0
12
Final
diagnosis
Asthma
Asthma
Asthma
Asthma
n = 318 (+5)
8 mg/ml 111 5
105
4
172
Asthma
Asthma
Asthma(?)
None
Figure 2. Decision tree starting with reversibility criterion followed by PC20 criterion. Note that 5 PEF missing in the < 9% reversibility branch 
(see Results).
PC20 histamine of -0.40 to -0.50.12,17 These studies were carried 
out with patients with an established diagnosis of asthma. For 
this group, the question as to whether PC20 can be replaced by 
PEF variability as a diagnostic tool is less relevant. This question 
is particularly relevant for subjects with signs or symptoms sus­
picious of asthma but without an established diagnosis. Trigg et 
a l]t> studied subjects from general practice with and without res­
piratory symptoms, and found figures similar to our results. A 
possible explanation of the low correlation might be the subclini- 
cal form of the disease in both Trigg et a/’s study19 and our pop­
ulation.
Another explanation is related to the method applied to 
express peak flow variation. We used the arithmetic mean of 
PEF measurements over a three-week period in our correlation, 
and this might disguise clinically relevant high PEF variability 
for only a few days. Therefore, the correlation between the num­
ber of days of a PEF variability of 2: 15% and PC20 histamine 
was also assessed. However, this did not essentially change the 
outcome (r = -0.26). More frequent measurement, e.g. four times 
a day, would probably have increased the PEF variability,13 but it
is very unlikely that this would have increased the correlation 
substantially. From our analysis, it became clear that with a PEF 
variability of 15% the sensitivity is almost zero, and thus not 
very applicable for use in everyday practice. A decrease in the 
PEF variability would increase the sensitivity, but then the values 
come so close to normal variability that the findings would lack
any specificity.
BHR assessment generally refers to PC20 histamine assessing 
BHR. When this is the case, PEF variability cannot replace this. 
The use of PEF measurements in general practice should be 
reserved for assessing reversibility.7 The practical implication of 
this is that BHR testing would require access to a function labo­
ratory. Although it is possible to perform a provocation test at the 
surgery,26 testing in a laboratory setting is preferred for reasons 
of safety and technical quality of the test performance.
In conclusion, the results of this study suggest that PEF cannot 
replace PC20 in testing BHR for the diagnosis of asthma. Where 
BHR is used as an inclusion criterion for asthma it should be 
tested by the PC20. This has consequences for the possibility of 
diagnosing asthma in primary care, where there is no easy access 
to a histamine challenge test.
British Journal of General Practice, August 1997 491
M i
J J Den Otter, G M W Reijnen Original papers
References 24.
1.
2.
3.
4.
5.
6.
7
8
9 .
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21 .
22.
23.
Anonymous. Guidelines for the diagnosis and management of asth­
ma. National Heart, Lung, and Blood Institute. National Asthma 
Education Program. Expert Panel Report. J Allergv Clin Immunol 
1991; 88: 425-534.
Anonymous. Standardization of spirometry - 1987 update. Statement 
of the American Thoracic Society. Am Rev Rexpir Dis 1987; 136:
1285-1298.
Schayck CP van, Weel C van, Harbers HJ, Herwaarden CLA van.
Do physical signs reflect the degree of airflow obstruction in patients 
with asthma or chronic obstructive pulmonary disease? Sccmcl J Prim 
Health Care 1991; 9: 232-238,
Newman-Taylor A. Environmental determinants of asthma. Lancet 
1995;345:296-299.
Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discon­
tinuing inhaled budesonide in patients with mild asthma. N Engl J 
Med 1994; 331: 700-705.
Sheffer AL, Taggart VS. The National Asthma Education Program. 
Expert panel report guidelines for the diagnosis and management of 
asthma. National Heart, Lung, and Blood Institute. Med Care 1993; 
31: 20-28.
Dekker FW, Schrier AC, Sterk PJ, Dijkman JH. Validity of peak 
expiratory flow measurement in assessing reversibility of airflow 
obstruction. Thorax 1992; 47: 162-166.
Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness. 
Standardized challenge testing with pharmacological, physical and 
sensitizing stimuli in adults. Report Working Party Standardization 
of Lung Function Tests, European Community for Steel and Coal. 
Official Statement of the European Respiratory Society. Eur RespirJ 
Suppl 1993; 16:53-83.
Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and 
forced ventilatory flows. Report Working Party Standardization of 
Lung Function Tests, European Community for Steel and Coal. 
Official Statement of the European Respiratory Society. Eur Respir J 
Suppl 1993; 16: 5-40.
Cockcroft DW, Hargreave FE. Airway hyperresponsiveness. 
Relevance of random population data to clinical usefulness. Am Rev 
Respir Dis 1990; 142: 497-500.
Rijcken B, Schouten JP, Weiss ST, et al. The distribution of 
bronchial responsiveness to histamine in symptomatic and in asymp­
tomatic subjects. A population-based analysis of various indices of 
responsiveness. Am Rev Respir Dis 1989; 140: 615-623.
Ryan G, Latimer KM, Dolovich J, Hargreave FE. Bronchial respon­
siveness to histamine: relationship to diurnal variation of peak flow 
rate, improvement after bronchodilator, and airway calibre. Thorax 
1982;37:423-429.
Anonymous. Guidelines for the diagnosis of occupational asthma. 
Subcommittee on ‘Occupational Allergy’ of the European Academy 
of Allergology and Clinical Immunology. Clin Exp Allergy 1992;
22: 103-108.
Schayck CP van. Diagnosis of asthma and chronic obstructive 
pulmonary disease in general practice. B rJ  Gen Pract 1996; 46:
193-197.
Quackenboss JJ, Lebowitz MD, Krzyzanowski M. The normal range 
of diurnal changes in peak expiratory How rates. Relationship to 
symptoms and respiratory disease. Am Rev Respir Dis 1991; 143: 
323-330.
Neukirch F, Liard R, Segala C, et al. Peak expiratory flow variability 
and bronchial responsiveness to methacholine, An epidemiologic 
study in 117 workers. Am Rev Respir Dis 1992; 146: 71-75.
Kerstjens HA, Brand PL, de Jong PM, et al. Influence of treatment 
on peak expiratory flow and its relation to airway hyperresponsive­
ness and symptoms. The Dutch CNSLD Study Group. Thorax 1994; 
49: 1109-1115.
Tirimanna PRS, Schayck CP van, Otter JJ den, et al. Prevalence of 
asthma and COPD in general practice: has it changed since 1977? Br 
J Gen Pract 1996; 46: 277-281.
Trigg CJ, Bennett JB, Tooley M, et al. A general practice based sur­
vey of bronchial hyperresponsiveness and its relation to symptoms, 
sex, age, atopy, and smoking. Thorax 1990; 45: 866-872.
Lende R van, One NGM. The MRC-ECCS questionnaire on respira­
tory symptoms (use in epidemiology), Scand J Respir Dis 1972; 53: 
218-226.
Higgins BG, Britton JR, Chinn S, et al. The distribution of peak 
expiratory flow variability in a population sample. Am Rev Respir 
Dis 1989; 140: 1368-1372.
Dompeling E, Schayck CP van, Folgering HTM, et al. Accuracy, 
precision and linearity of the portable flow-volume meter Microspiro 
HI-298. Eur RespirJ 1991; 4: 612-615.
Keeley D. Large volume plastic spacers in asthma. BMJ 1992; 305: 
598-599,
25.
26.
Dales RE, Spitzer WO, Tousignant P, et al. Clinical interpretation of 
airway response to a bronchodilator. Epidemiologic considerations.
Am Rev Respir Dis 1988; 138:317-320.
Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE. Bronchial 
reactivity to inhaled histamine: a method and clinical survey. Clin 
Allergy 1977; 7: 235-243.
Yan K, Salome C, Woolcock AJ. Rapid method for measurement of 
bronchial responsiveness. Thorax 1983; 38: 760-765.
Address for correspondence
Joost J den Otter, Nijmegen University internal code 229, Faculty of 
Medical Sciences, Department of General Practice and Social Medicine, 
PO Box 9101, 6500 HB Nijmegen, The Netherlands.
um
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18-19 September 1997 
Venue: The Commonwealth Institute, London
Addressing the difficult question of “whose quality is it anyway?”, 
this Symposium will consider how patients, clinicians and  
managers can work together to achieve the highest quality  
patient care. The programme will consist of formal p ap er  
sessions; interactive Workshops, and Poster Displays.
Many of the Task Groups from the Quality & Clinical Networks 
will be presenting leading edge work from their specialist areas. 
The wide range of topics will include:
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Inner City Medicine 
Risk Management (Medico-legal)
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Palliative Care 
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Rural Medicine 
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Prescribing
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For further details please contact:
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